NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
COMBIPATCH (estradiol/norethindrone acetate transdermal system) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause. First approved in 1998.
Drug data last refreshed 5h ago · AI intelligence enriched 5h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPATCH is a transdermal estradiol/norethindrone acetate patch approved in 1998 for treating moderate to severe vasomotor symptoms (hot flashes) in menopausal women with an intact uterus. It delivers combined estrogen and progestin hormones through the skin as an extended-release film. The mechanism works via estrogen receptor agonism to alleviate menopausal symptoms.
$5MPart D
LOE ApproachingDeclining
Product is in late lifecycle phase with modest Part D claims (11,543 in 2023), signaling a shrinking brand team focused on retention rather than growth initiatives.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Career Relevance
Career opportunities on COMBIPATCH are concentrated in manufacturing and quality functions rather than commercial or medical roles, reflecting a mature product focused on operational excellence and compliance. Roles support manufacturing continuity, supply chain stability, and regulatory adherence rather than growth initiatives.
Worked on COMBIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.